Dr. Rizzo discusses how the 31-gene expression profile (31-GEP) test enhances prognostic assessment in patients with cutaneous melanoma, with a focus on how it can guide routine imaging decisions and improve risk stratification. His presentation highlights the role of molecular diagnostics in identifying patients who may benefit from closer surveillance and earlier intervention.
Topics Covered
- How the 31-GEP test supports melanoma risk stratification
- Using gene expression data to guide imaging and surveillance strategies
- Evidence linking 31-GEP–guided imaging to earlier detection of metastasis
- The role of molecular testing in personalized melanoma care
References
- Dhillon S, Duarte-Bateman D, Fowler G, et al. Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. Archives of Dermatological Research. 2023;315(8):2295–2302.
- Durgham RA, Nassar SI, Gun R, et al. The prognostic value of the 31-gene expression profile test in cutaneous melanoma: a systematic review and meta-analysis. Cancers. 2024;16(21):3714.
Explore Related Resources
